

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48	A2	(11) International Publication Number: WO 97/26919
		(43) International Publication Date: 31 July 1997 (31.07.97)

(21) International Application Number: PCT/US97/00251

(22) International Filing Date: 2 January 1997 (02.01.97)

(30) Priority Data:
60/010,495 24 January 1996 (24.01.96) US

(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAPRATHE, Bradley, William [US/US]; 31450 Myrna, Livonia, MI 48154 (US). GILMORE, John, Lodge [US/US]; Apartment 178C, 3695 Greenbrier Boulevard, Ann Arbor, MI 48105 (US). HAYS, Sheryl, Jeanne [US/US]; 2729 Aspen Road, Ann Arbor, MI 48108 (US). JAEN, Juan, Carlos [US/US]; 10680 Red Maple Drive, Plymouth, MI 48170 (US). LEVINE, Harry, III [US/US]; 3790 Bradford Square Drive, Ann Arbor, MI 48103 (US).

(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.

(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD OF IMAGING AMYLOID DEPOSITS

(57) Abstract

The present invention provides a method of imaging amyloid deposits and radiolabeled compounds useful in imaging amyloid deposits. The invention also provides a method of delivering a therapeutic agent to amyloid deposits, a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of determining a compound's ability to inhibit aggregation of amyloid proteins.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

METHOD OF IMAGING AMYLOID DEPOSITS

5

FIELD OF THE INVENTION

10 This invention relates to a method of imaging amyloid deposits and to labeled compounds useful in imaging amyloid deposits. This invention also relates to a method of delivering a therapeutic agent to amyloid deposits, a method of inhibiting the aggregation of amyloid proteins to form amyloid
15 deposits, and a method of determining a compound's ability to inhibit aggregation of amyloid proteins.

BACKGROUND OF THE INVENTION

20

Amyloidosis is a condition characterized by the accumulation of various insoluble, fibrillar proteins in the tissues of a patient. The fibrillar proteins that comprise the accumulations or deposits are called
25 amyloid proteins. While the particular proteins or peptides found in the deposits vary, the presence of fibrillar morphology and a large amount of β -sheet secondary structure is seen in many types of amyloids. An amyloid deposit is formed by the aggregation of
30 amyloid proteins, followed by the further combination of aggregates and/or amyloid proteins.

The presence of amyloid deposits has been shown in various diseases such as Mediterranean fever, Muckle-Wells syndrome, idiopathic myeloma, amyloid
35 polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Alzheimer's disease, Down's syndrome, Scrapie, Creutzfeldt-Jacob disease, Kuru, Gerstmann-Strausler-Scheinker syndrome,

-2-

medullary carcinoma of the thyroid, Isolated atrial amyloid, β_2 -microglobulin amyloid in dialysis patients, inclusion body myositis, β_2 -amyloid deposits in muscle wasting disease, and Islets of Langerhans diabetes
5 Type II insulinoma.

Thus, a simple, noninvasive method for detecting and quantitating amyloid deposits in a patient has been eagerly sought. Presently, detection of amyloid
10 deposits involves histological analysis of biopsy or autopsy materials. Both methods have major drawbacks. For example, an autopsy can only be used for a postmortem diagnosis.


The direct imaging of amyloid deposits in vivo is difficult, as the deposits have many of the same
15 physical properties (i.e., density and water content) as normal tissues. Attempts to image amyloid deposits using magnetic resonance imaging (MRI) and computer-assisted tomography (CAT) have been disappointing and have detected amyloid deposits only under certain
20 favorable conditions. In addition, efforts to label amyloid deposits with antibodies, serum amyloid P protein, or other probe molecules has provided some selectivity on the periphery of tissues, but has provided for poor imaging of tissue interiors.

25 Thus, it would be useful to have a noninvasive technique for imaging and quantitating amyloid deposits in a patient. In addition, it would be useful to have compounds that inhibit the aggregation of amyloid proteins to form amyloid deposits and a method for
30 determining a compound's ability to inhibit amyloid protein aggregation.


-3-

SUMMARY OF THE INVENTION

The present invention provides a method of imaging amyloid deposits, the method comprising introducing
 5 into a patient a detectable quantity of a labeled compound having the Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof



15 wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration;
 Z is



25 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

30 R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

35 A is -O-, -S-, $-NR^4-$, C=O, or a single bond;

- 4 -

- Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;
- R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, -CO-aryl, or arylthio;
- R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or - NR^4R^5 represents a 5-, 6- or 7-membered ring containing nitrogen; and
- R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or C_1 - C_6 thioalkoxy; allowing sufficient time for the labeled compound to become associated with amyloid deposits; and detecting the labeled compound associated with the amyloid deposits.

- In a preferred embodiment of the compound having Formula I, $X=Y$ is $C=C$ or $N=N$;
- R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogen, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane or cyclohexane ring that is fused to the phenyl ring;
- R^3 is C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkenyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;
- m is 1 to 5 and n is 0 to 4;
- A is -O-, -S-, or a single bond;
- Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;
- R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, aryloxy, -CO-aryl, or arylthio;
- R^4 and R^5 are each independently hydrogen or C_1 - C_6 alkyl; and
- R^6 is hydrogen, C_1 - C_6 alkyl, or halogen.

-5-

In another preferred embodiment of the compound having Formula I, $X=Y$ is $C=C$ or $N=N$;

R^1 and R^2 are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, nitro, or R^1 and R^2 combined form a (4,5), (5,6), or (6,7) benzene ring that is fused to the phenyl ring;

R^3 is C_1-C_{10} alkyl, C_2-C_{10} alkenyl, arylalkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$; m is 2 to 4 and n is 0 to 3;

A is $-O-$, or a single bond;

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

R^7 is hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, halogen, aryl, aryloxy, or $-CO$ -aryl;


R^4 and R^5 are each independently hydrogen, methyl, ethyl, n -propyl or n -butyl; and

R^6 is hydrogen or halogen.

In another aspect, the present invention provides a method of delivering a therapeutic agent to an amyloid deposit comprising introducing into a patient a compound having the formula

$$A-B-C$$


or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein A is



X and Y are each independently C or N and the $X=Y$ double bond has the trans configuration;

-6-

Z is



10 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

15 R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

A is $-O-$, $-S-$, $-NR^4-$, $C=O$, or a single bond;

20 Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

25 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, $-CO$ -aryl or arylthio;

R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or $-NR^4R^5$ represents a 5-, 6-, or 7-membered ring containing nitrogen; and

30 R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro or C_1 - C_6 thioalkoxy;


B is a linking moiety or a bond; and

C is a therapeutic agent.


35 The present invention also provides a method of inhibiting the aggregation of amyloid proteins to form

-7-

amyloid deposits, the method comprising administering to a patient an amyloid protein aggregation inhibiting amount of a compound of Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof



wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration;
Z is



R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

A is -O-, -S-, -NR⁴-, C=O, or a single bond;

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6


- 8 -

thioalkoxy, aryl, heteroaryl, aryloxy, -CO-aryl,
or arylthio;


R⁴ and R⁵ are each independently hydrogen, C₁-C₆ alkyl
or -NR⁴R⁵ represents a 5-, 6- or 7-membered ring
5 containing nitrogen; and

R⁶ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy,
halogen, amino, di(C₁-C₆ alkyl)amino, nitro, or
C₁-C₆ thioalkoxy.

10 The present invention also provides a method for
determining a compound's ability to inhibit the
aggregation of amyloid proteins, the method comprising
combining solutions of the compound with amyloid
proteins under conditions that are known to lead to
15 amyloid protein aggregation; introducing into the
solution a labeled compound of Formula I or a
pharmaceutically acceptable salt, ester, amide, or
prodrug thereof



25 wherein X and Y are each independently C or N and the
X=Y double bond has the trans configuration;
Z is




35

-9-

- R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;
- R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;
- m is 1 to 6 and n is 0 to 6;
- A is $-O-$, $-S-$, $-NR^4-$, $C=O$, or a single bond;
- Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;
- R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, $-CO$ -aryl, or arylthio;
- R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or $-NR^4R^5$ represents a 5-, 6- or 7-membered ring containing nitrogen; and
- R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or C_1 - C_6 thioalkoxy; filtering or centrifuging the solution; and determining the amount of labeled compound in the filtrate or supernatant.


Also provided is a compound of the Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof



-10-

wherein X and Y are each independently C or N and the
 X=Y double bond has the trans configuration;
 Z is

5



10 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl,
 C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6
 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6
 thioalkoxy, or R^1 and R^2 combined form a benzene,
 15 cyclopentane, or cyclohexane ring that is fused to
 the phenyl ring;

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10}
 alkenyl, arylalkyl, (heteroaryl)alkyl,
 (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or
 $-(CH_2)_m-A-(CH_2)_n-Q$;

20 m is 1 to 6 and n is 0 to 6;

A is $-O-$, $-S-$, $-NR^4-$, $C=O$, or a single bond;

Q is phenyl substituted with R^7 or naphthyl substituted
 with R^7 ;

25 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy,
 halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6
 thioalkoxy, aryl, heteroaryl, aryloxy, $-CO$ -aryl,
 or arylthio;

R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl
 or $-NR^4R^5$ represents a 5-, 6- or 7-membered ring
 30 containing nitrogen; and

R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy,
 halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or
 C_1 - C_6 thioalkoxy,

35 and one or more atoms in the compound has been replaced
 with a radioisotope.

-11-

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the inhibition of binding of ThT to insulin amyloid by compounds of Formula I.


5 Figure 2 shows the inhibition of binding of a radiolabeled compound of the present invention to insulin amyloid by nonradiolabeled compound as a function of the concentration of the compound.

10

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method of imaging amyloid deposits that comprises introducing into a
15 tissue or a patient a detectable quantity of a labeled compound of Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof

20




I

25

wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration;
Z is

30



35

R¹ and R² are each independently hydrogen, C₁-C₆ alkyl,
C₁-C₆ alkoxy, hydroxy, halogen, amino,
mono(C₁-C₆ alkyl)amino, di(C₁-C₆ alkyl)amino,

-12-

nitro, C₁-C₆ thioalkoxy, or R¹ and R² combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

R³ is a lone pair of electrons, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

A is -O-, -S-, -NR⁴-, C=O, or a single bond;

Q is phenyl substituted with R⁷ or naphthyl substituted with R⁷;

R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, halogen, amino, di(C₁-C₆ alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl, heteroaryl, aryloxy, -CO-aryl, or arylthio;

R⁴ and R⁵ are each independently hydrogen, C₁-C₆ alkyl or -NR⁴R⁵ represents a 5-, 6- or 7-membered ring containing nitrogen; and

R⁶ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, halogen, amino, di(C₁-C₆ alkyl)amino, nitro, or C₁-C₆ thioalkoxy;

allowing sufficient time for the labeled compound to become associated with amyloid deposits; and detecting the labeled compound associated with the amyloid deposits.

In a preferred embodiment of the invention,

X=Y is C=C or N=N;

R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, nitro, C₁-C₆ thioalkoxy, or R¹ and R² combined form a benzene, cyclopentane or cyclohexane ring that is fused to the phenyl ring;

R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkenyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 5 and n is 0 to 4;

A is -O-, -S-, or a single bond;

-13-

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, aryloxy, -CO-aryl, or arylthio;

R^4 and R^5 are each independently hydrogen or C_1 - C_6 alkyl; and

R^6 is hydrogen, C_1 - C_6 alkyl, or halogen.

In a more preferred embodiment of the invention,

X=Y is C=C or N=N;

R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogen, nitro, or R^1 and R^2 combined form a (4,5), (5,6), or (6,7) benzene ring that is fused to the phenyl ring;

R^3 is C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 2 to 4 and n is 0 to 3;

A is -O-, or a single bond;

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, aryl, aryloxy, or -CO-aryl;

R^4 and R^5 are each independently hydrogen, methyl, ethyl, n-propyl or n-butyl; and

R^6 is hydrogen or halogen.

In a most preferred embodiment of the invention, the labeled compound is

(E)-{4-[2-(5-Chlorobenzothiazol-2-yl)vinyl]-phenyl}dimethylamine;

(E)-{4-[2-Benzothiazol-2-yl)vinyl]}phenyl}-dimethylamine;

(E)-Dimethyl-{4-[2-(5-methylbenzothiazol-2-yl)-vinyl]phenyl}amine;

(E)-Dimethyl-{4-[2-(6-methylbenzothiazol-2-yl)-vinyl]phenyl}amine;

-14-

(E)-{2-[2-(4-Dimethylaminophenyl)vinyl]benzothiazol-6-yl}dimethylamine;

(E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium bromide;

5 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-ethylbenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-methylnaphtho[1,2-d]thiazol-3-ium iodide;

10 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylbenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-allylbenzothiazol-3-ium bromide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-butylbenzothiazol-3-ium iodide;

15 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide;

(E)-5-Chloro-2-[2-(4-dimethylaminophenyl)vinyl]-3-methylbenzothiazol-3-ium iodide;

20 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-5-fluoro-3-methylbenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-benzyl-5-fluorobenzothiazol-3-ium bromide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,5-dimethylbenzothiazol-3-ium iodide;

25 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,6-dimethylbenzothiazol-3-ium iodide;

(E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)vinyl]-6-methylbenzothiazol-3-ium bromide;

30 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptyl-6-methoxybenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methyl-6-nitrobenzothiazol-3-ium toluene-4-sulfonate;

35 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-ethylnaphtho[1,2-d]thiazol-1-ium toluene-4-sulfonate;

-15-

- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylnaphtho[2,3-d]thiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylnaphtho[2,1-d]thiazol-3-ium iodide;
- 5 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-fluorobenzyl)benzothiazol-3-ium bromide;
- (E)-3-Biphenyl-4-ylmethyl-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-naphthalen-2-ylmethylbenzothiazol-3-ium bromide;
- 10 (E)-3-Biphenyl-2-ylmethyl-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium bromide;
- (E)-3-(3-Benzoylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium bromide;
- 15 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenoxybenzyl)benzothiazol-3-ium bromide
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenylpropyl)benzothiazol-3-ium iodide;
- (E,E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenylallyl)benzothiazol-3-ium bromide;
- 20 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4,4-diphenylbutyl)benzothiazol-3-ium iodide;
- (E)-3-(3-Benzylloxypropyl)-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- 25 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-phenoxybutyl)benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenylpentyl)benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenoxyphenyl)benzothiazol-3-ium iodide;
- 30 (E)-3-(2-Cyclohexylethyl)-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-3-heptylbenzothiazol-3-ium iodide;
- 35 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(2-hydroxyethyl)benzothiazol-3-ium bromide;

-16-

(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide;

(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-1-methylnaphtho[1,2-d]thiazol-1-ium toluene-4-sulfonate;

5 (E)-2-[2-(4-Diethylaminophenyl)vinyl]-3-methylbenzothiazol-3-ium chlorldide;

(E)-2-[2-(4-Dibethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide;

10 (E)-2-[2-(4-Dibutylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide;

(E)-3-Heptyl-2-[2-[(4-pyrrolidin-1-yl)phenyl]vinyl]benzothiazol-3-ium iodide;

[4-(Dimethylamino)phenylazo]benzothiazole;

4-(Benzothiazol-2-ylazo)naphthalen-1-ylamine;

15 2-[[4-(Dimethylamino)phenyl]azo]-6-methoxybenzothiazole;

6-Chloro-2-[[4-(dimethylamino)phenyl]azo]benzothiazole;

20 [4-(6-Methoxybenzothiazol-2-ylazo)naphthalen-1-yl]dimethylamine;

Dimethyl[4-(naphtho[1,2-d]thiazol-2-ylazo)-naphthalen-1-yl]-amine;

2-[[4-(Dimethylamino)phenyl]azo]-6-methoxy-3-methylbenzothiazol-3-ium methylsulfate; and

25 2-[[4-(Dimethylamino)phenyl]azo]-3-methylbenzothiazolium methylsulfate.

It is recognized that many of the compounds above are salts. The free (nonsalt) compounds are also intended.

30 The term "alkyl" means a straight or branched chain hydrocarbon. Representative examples of alkyl groups are methyl, ethyl, propyl, isopropyl, isobutyl, butyl, tert-butyl, sec-butyl, pentyl, and hexyl.

35 The term "alkoxy" means an alkyl group attached to an oxygen atom. Representative examples of alkoxy

-17-

groups include methoxy, ethoxy, tert-butoxy, propoxy, and isobutoxy.

The term "halogen" includes chlorine, fluorine, bromine, and iodine.

5 The term "di(alkyl)amine" means an amine group having two hydrogens replaced by alkyl groups. Representative examples of di(alkyl)amines are dimethylamine, diethylamine, and methylethylamine.

10 The term "alkylenyl" means a branched or straight chain hydrocarbon containing one or more carbon-carbon double bond.

The term "aryl" means an aromatic hydrocarbon. Representative examples of aryl groups include phenyl and naphthyl.

15 The term "arylalkyl" means an alkyl group substituted with an aryl group. Representative examples are benzyl and phenylethyl.

The term "heteroatom" includes oxygen, nitrogen, and sulfur.

20 The term "heteroaryl" means an aryl group wherein one or more carbon atom of the aromatic hydrocarbon has been replaced with a heteroatom.

The term "(heteroaryl)alkyl" means an alkyl group substituted with a heteroaryl group.

25 The term "cycloalkyl" means a cyclic hydrocarbon. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "arylalkenyl" means an alkenyl group substituted with an aryl group.

30 The term "diarylalkyl" means an alkyl group substituted with two aryl groups.

The term "aryloxy" means an aryl group attached to an oxygen atom.

35 The term "arylthio" means an aryl group attached to a sulfur atom.

-18-

The term "thioalkoxy" means an alkyl group attached to a sulfur atom.

The symbol "-" means a covalent bond.

The term "pharmaceutically acceptable salt, ester, amide, and prodrug" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as, nontoxic ammonium, quaternary ammonium and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example,

-19-

Berge S.M., et al., Pharmaceutical Salts, J. Pharm. Sci., 66:1-19 (1977) which is incorporated herein by reference.)

5 Examples of pharmaceutically acceptable, nontoxic esters of the compounds of this invention include C₁-C₆ alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C₅-C₇ cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C₁-C₄ alkyl esters are
10 preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

 Examples of pharmaceutically acceptable, nontoxic amides of the compounds of this invention include
15 amides derived from ammonia, primary C₁-C₆ alkyl amines and secondary C₁-C₆ dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen
20 atom. Amides derived from ammonia, C₁-C₃ alkyl primary amides and C₁-C₂ dialkyl secondary amides are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.

 The term "prodrug" refers to compounds that are
25 rapidly transformed in vivo to yield the parent compound of the above formulas, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium
30 Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

 In addition, the compounds of the present
35 invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as

-20-

water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

5 The compounds of the present invention can exist in different stereoisometric forms by virtue of the presence of asymmetric centers in the compounds. It is contemplated that all stereoisometric forms of the compounds, as well as mixture thereof, including racemic mixtures, form part of this invention.

10 In the first step of the present method of imaging, a labeled compound of Formula I is introduced into a tissue or a patient in a detectable quantity. The compound is typically part of a pharmaceutical composition and is administered to the tissue or the
15 patient by methods well known to those skilled in the art.

For example, the compound can be administered either orally, rectally, parenterally (intravenous, by intramuscularly or subcutaneously), intracisternally,
20 intravaginally, intraperitoneally, intravesically, locally (powders, ointments or drops), or as a buccal or nasal spray.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or
25 nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols
30 (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by
35 the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

-21-

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders, as for example paraffin; (f) absorption accelerators, as for example, quaternary ammonium compounds; (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite; and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft- and hard-filled gelatin

-22-

capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethyleneglycols, and the like.

5 Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a
10 certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned
15 excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage
20 forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol,
25 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these
30 substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

35 Suspensions, in addition to the active compounds, may contain suspending agents, as for example,

-23-

ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and
5 the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable nonirritating excipients or carriers such as
10 cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of a
15 compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or propellants as may be required. Ophthalmic
20 formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

In a preferred embodiment of the invention, the labeled compound is introduced into a patient in a
25 detectable quantity and after sufficient time has passed for the compound to become associated with amyloid deposits, the labeled compound is detected noninvasively inside the patient. In another embodiment of the invention, a labeled compound of
30 Formula I is introduced into a patient, sufficient time is allowed for the compound to become associated with amyloid deposits, and then a sample of tissue from the patient is removed and the labeled compound in the tissue is detected apart from the patient. In a third
35 embodiment of the invention, a tissue sample is removed from a patient and a labeled compound of Formula I is

-24-

introduced into the tissue sample. After a sufficient amount of time for the compound to become bound to amyloid deposits, the compound is detected.

5 The administration of the labeled compound to a patient can be by a general or local administration route. For example, the labeled compound may be administered to the patient such that it is delivered throughout the body. Alternatively, the labeled
10 compound can be administered to a specific organ or tissue of interest. For example, it is desirable to locate and quantitate amyloid deposits in the brain in order to diagnose or track the progress of Alzheimer's disease in a patient.

The term "tissue" means a part of a patient's
15 body. Examples of tissues include the brain, heart, liver, blood vessels, and arteries. A detectable quantity is a quantity of labeled compound necessary to be detected by the detection method chosen. The amount of a labeled compound to be introduced into a patient
20 in order to provide for detection can readily be determined by those skilled in the art. For example, increasing amounts of the labeled compound can be given to a patient until the compound is detected by the detection method of choice. A label is introduced into
25 the compounds to provide for detection of the compounds.

The term "patient" means humans and other animals. Those skilled in the art are also familiar with determining the amount of time sufficient for a
30 compound to become associated with amyloid deposits. The amount of time necessary can easily be determined by introducing a detectable amount of a labeled compound of Formula I into a patient and then detecting the labeled compound at various times after
35 administration.

-25-

The term "associated" means a chemical interaction between the labeled compound and the amyloid deposit. Examples of associations include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions, and complexes.

Those skilled in the art are familiar with the various ways to detect labeled compounds. For example, magnetic resonance imaging (MRI), positron emission tomography (PET), or single photon emission computed tomography (SPECT) can be used to detect radiolabeled compounds. The label that is introduced into the compound will depend on the detection method desired. For example, if PET is selected as a detection method, the compound must possess a positron-emitting atom, such as ^{11}C or ^{18}F .

Another example of a suitable label in a compound of Formula I is an atom such as ^{13}C , ^{15}N , or ^{19}F which can be detected using magnetic resonance imaging (MRI) which is also sometimes called nuclear magnetic resonance (NMR). In addition, the labeled compounds of Formula I may also be detected by MRI using paramagnetic contrast agents.

Another example of detection is electron paramagnetic resonance (EPR). In this case, EPR probes which are well-known in the art, such as nitroxides, can be used.

The imaging of amyloid deposits can also be carried out quantitatively so that the amount of amyloid deposits can be determined.

The present invention also provides a method of delivering a therapeutic agent to an amyloid deposit comprising introducing into a patient a compound having the formula


35

A-B-C

-26-

or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, wherein A is

5




10

X and Y are each independently C or N and the X=Y double bond has the trans configuration;

Z is

15



20

R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

25

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

A is -O-, -S-, $-NR^4-$, C=O, or a single bond;

30

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, -CO-aryl or arylthio;

35

-27-

R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or $-NR^4R^5$ represents a 5-, 6-, or 7-membered ring containing nitrogen; and

5 R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or C_1 - C_6 thioalkoxy;

B is a linking moiety or a bond; and

C is a therapeutic agent.

10 The linking moiety B can be any linking moiety known to those skilled in the art. The linking moiety is used to attach the therapeutic agent C to a Compound A that binds to amyloids deposits. Examples of suitable linking moieties include, but are not limited to, covalent bonds, amino acids, peptides or
15 proteins, alkyl chains, hydroxyacids, and diacids.

The therapeutic agent C can be any therapeutic agent known to those skilled in the art. In particular, the therapeutic agent is one that is intended for delivery to amyloid deposits or to the
20 organs containing amyloid deposits. For example, the therapeutic agent can block or inhibit the growth or toxicity of amyloid deposits. The therapeutic agents can also aid in the degradation of amyloid deposits such as through proteolytic degradation. Examples of
25 suitable therapeutic agents include, but are not limited to, nonsteroidal anti-inflammatory compounds (NSAIDS) such as ibuprofen or indomethacin, or compounds that affect the rate of production of the amyloid proteins.

30 The present invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, by administering to a patient an amyloid inhibiting amount of a compound of Formula I. Those skilled in the art are readily able to determine
35 an amyloid inhibiting amount by simply administering a compound of Formula I to a patient in increasing

-28-

amounts until the growth of amyloid deposits is decreased or stopped. The rate of growth can be assessed using imaging as described above or by taking a tissue sample from a patient and observing the amyloid deposits therein.

The present invention also provides a method for determining a compound's ability to inhibit the aggregation of amyloid proteins. The method comprises combining the compound to be tested with amyloidogenic proteins under conditions known to produce amyloid aggregates, introducing into the assay vessel solution a labeled compound of Formula I, filtering or centrifuging the solution and determining the amount of labeled compound in the filter or filtrate, or supernatant.

The compounds of Formula I bind amyloid deposits or aggregated amyloid proteins preferentially to soluble pre-amyloid proteins. Thus, if the pre-amyloid proteins in solution aggregate, compounds of Formula I will bind to the aggregates and amyloid deposits and the associated labeled compound will be retained by the filter. However, if aggregation is inhibited by the compound of interest, then the labeled compound of Formula I will not bind to the amyloid proteins and will pass through the filter.

The compounds to be tested for ability to inhibit the aggregation of amyloid proteins can be any compound in which one skilled in the art suspects have amyloid aggregation inhibiting activity or can be chosen at random from a natural product or chemical libraries. The solution can be any solution in which amyloid proteins, a compound to be tested and a compound of Formula I are soluble. Preferably, the solution is an aqueous solution. The label may be any label known to those skilled in the art that can be detected and

-29-

quantitated. For example, a preferred label is a radiolabel.

Also provided by the present invention are compounds of Formula I wherein one or more atom in the compound has been replaced with a radioisotope. The radioisotope can be any radioisotope. However, ^3H , ^{123}I , ^{125}I , ^{131}I , ^{11}C , and ^{18}F are preferred.

The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is sufficient. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.

The examples presented below are intended to illustrate particular embodiments of the invention and are not intended to limit the scope of the specification, including the claims, in any manner.

25

EXAMPLES

Synthesis of Compounds of Formula I and Labeled Compounds of Formula I

30

EXAMPLE 1

(E)-[4-[2-(5-Chlorobenzothiazol-2-yl)vinyl]phenyl]-dimethylamine

The procedure of Cuadro, et al., Il Farmaco, 47:477-488 (1992), was followed. A suspension of

35

-30-

2-methyl-5-chloro-benzothiazole (3.78 g, 20.6 mmol),
4-(dimethylamino)benzaldehyde (3.04 g, 20.4 mmol), and
0.5 g of benzyltriethylammonium chloride in 30 mL of
5 50% aqueous sodium hydroxide solution was mechanically
stirred in an ultrasonic bath at room temperature for
12 hours. Water (20 mL) was added, the mixture was
cooled, filtered, and the solid was washed with water
to give the title compound as a yellow solid,
mp 182-184°C.

10

EXAMPLE 2

(E)-[4-[2-(Benzothiazol-2-yl)vinyl]phenyl]-
dimethylamine was purchased from the Aldrich Chemical
Co.

15

In a process analogous to Example 1, using
appropriately substituted 2-methylbenzothiazoles, the
corresponding compounds were prepared as follows:

EXAMPLE 3

20

(E)-Dimethyl-[4-[2-(5-methylbenzothiazol-2-yl)vinyl]-
phenyllamine, mp 192-194°C

EXAMPLE 4

25

(E)-Dimethyl-[4-[2-(6-methylbenzothiazol-2-yl)vinyl]-
phenyllamine, mp 219-220.5°C

EXAMPLE 5

30

(E)-[2-[2-(4-Dimethylaminophenyl)vinyl]benzothiazol-6-
yl]dimethylamine, mp 237-240°C

EXAMPLE 6

35

(E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)vinyl]-
benzothiazol-3-ium bromide

Step (a) 3-Benzyl-2-methylbenzothiazolium bromide

A solution of 2-methylbenzothiazole (5.0 g,
0.033 mol) and benzyl bromide (40 mL, 0.33 mol) in

-31-

250 mL of ethyl acetate was refluxed under nitrogen for 48 hours. Solid had formed. The mixture was filtered and washed with cold ethyl acetate to give 3-benzyl-2-methylbenzothiazol-3-ium bromide as a light yellow solid, mp 230-231°C.

Step (b) (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-benzylbenzothiazol-3-ium bromide

A mixture of 3-benzyl-2-methylbenzothiazol-3-ium bromide (0.30 g, 0.94 mmol) and 4-dimethylaminobenzaldehyde (0.21 g, 1.41 mmol) in 5 mL of acetic anhydride was heated under nitrogen. Upon refluxing, the mixture turned red and all solids appeared to be in solution. The solution was refluxed for 15 minutes, cooled, and filtered. The solid was washed with ethyl acetate to give (E)-2-[2-(4-dimethylaminophenyl)vinyl]-3-benzylbenzothiazol-3-ium bromide as a purple solid, mp 247-248°C, decomposed (dec).

EXAMPLE 7

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-ethylbenzothiazol-3-ium iodide was purchased from the Aldrich Chemical Co.

EXAMPLE 8

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-methyl-naphtho[1,2-d]thiazol-3-ium iodide was purchased from the Sigma Chemical Co.

In a process analogous to Example 2, appropriately substituted 2-methylbenzothiazoles were alkylated with various alkyl halides then condensed with 4-dimethylaminobenzaldehyde in acetic anhydride, the corresponding compounds were prepared as follows:

-32-

EXAMPLE 9

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methyl-
benzothiazol-3-ium iodide, 251-254°C, dec.

5

EXAMPLE 10

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-allyl-
benzothiazol-3-ium bromide, 237-240°C, dec.

EXAMPLE 11

10

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-butyl-
benzothiazol-3-ium iodide, 234-235°C, dec.

EXAMPLE 12

15

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptyl-
benzothiazol-3-ium iodide, 228-229°C, dec.

EXAMPLE 13

20

(E)-5-Chloro-2-[2-(4-dimethylaminophenyl)vinyl]-3-
methylbenzothiazol-3-ium iodide, 260-261°C, dec.

EXAMPLE 14

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-5-fluoro-
3-methylbenzothiazol-3-ium iodide, 250-251°C.

25

EXAMPLE 15

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-benzyl-
5-fluorobenzothiazol-3-ium bromide, 243-245°C.

EXAMPLE 16

30

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,5-dimethyl-
benzothiazol-3-ium iodide, 248-250°C, dec.

EXAMPLE 17

35

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,6-dimethyl-
benzothiazol-3-ium iodide, >240°C, dec.

-33-

EXAMPLE 18

(E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)vinyl]-6-methylbenzothiazol-3-ium bromide, 245-247°C, dec.

5

EXAMPLE 19

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide, 254-260°C, dec.

EXAMPLE 20

10 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptyl-6-methoxybenzothiazol-3-ium iodide, 207-208°C, dec.

EXAMPLE 21

15 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methyl-6-nitrobenzothiazol-3-ium toluene-4-sulfonate, 281-282°C, dec.

EXAMPLE 22

20 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-ethyl-naphtho[1,2-d]thiazol-3-ium toluene-4-sulfonate, >186°C, dec.

EXAMPLE 23

25 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methyl-naphtho[2,3-d]thiazol-3-ium iodide, 302-303°C, dec.

EXAMPLE 24

30 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methyl-naphtho[2,1-d]thiazol-3-ium iodide, 245-247°C, dec.

EXAMPLE 25

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-fluorobenzyl)benzothiazol-3-ium bromide, 254-255°C.

-34-

EXAMPLE 26

(E)-3-Biphenyl-4-ylmethyl-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium iodide, 210-213°C.

5

EXAMPLE 27

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-naphthalen-2-ylmethylbenzothiazol-3-ium bromide, 233-236°C.

EXAMPLE 28

10

(E)-3-Biphenyl-2-ylmethyl-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium bromide, 229-230°C.

EXAMPLE 29

15

(E)-3-(3-Benzoylbenzyl)-2-[2-(4-dimethylaminophenyl)-vinyl]benzothiazol-3-ium bromide, 231-233°C.

EXAMPLE 30

20

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenoxybenzyl)benzothiazol-3-ium bromide, 231-232°C.

EXAMPLE 31

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenylpropyl)benzothiazol-3-ium iodide, 268-269°C.

25

EXAMPLE 32

(E,E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenylallyl)benzothiazol-3-ium bromide, 220-222°C.

EXAMPLE 33

30

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4,4-diphenylbutyl)benzothiazol-3-ium iodide, 187-189°C.

EXAMPLE 34

35

(E)-3-(3-Benzoyloxypropyl)-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium iodide, 174-177°C.

-35-

EXAMPLE 35

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-phenoxy-butyl)benzothiazol-3-ium iodide, 165-170°C, dec.

5

EXAMPLE 36

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenyl-pentyl)benzothiazol-3-ium iodide, 214-217°C.

EXAMPLE 37

10 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenoxy-pentyl)benzothiazol-3-ium iodide, 156-158.5°C.

EXAMPLE 38

15 (E)-3-(2-Cyclohexylethyl)-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium iodide, 262-264°C.

EXAMPLE 39

(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-3-heptylbenzothiazol-3-ium iodide

20 Step (a) 3-Heptyl-2-methylbenzothiazolium iodide

A solution of 2-methylbenzothiazole (10.0 g, 0.067 mol) and 1-iodoheptane (110 mL, 0.67 mol) in 100 mL of acetonitrile was refluxed under nitrogen for 48 hours. The mixture was cooled, filtered, and the solid formed was washed with diethyl ether and recrystallized from ethanol-ethyl acetate to give 3-heptyl-2-methylbenzothiazolium iodide as a light purple solid, mp 110-113°C.

30 Step (b) (E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)-vinyl]-3-heptylbenzothiazol-3-ium iodide

A mixture of 3-heptyl-2-methylbenzothiazolium iodide (0.50 g, 1.33 mmol) and 4-dimethylamino-1-naphthaldehyde (0.40 g, 2.01 mmol) in 5 mL of acetic anhydride under nitrogen was heated. Upon refluxing, the mixture turned purple and all solids seemed to be

35

-36-

in solution. The solution was refluxed for 15 minutes and on cooling, solid formed. The mixture was filtered and washed with ethyl acetate to give (E)-2-[2-(4-dimethylaminonaphthalen-1-yl)vinyl]-3-heptylbenzothiazol-3-ium iodide as a dark brown solid, mp 195-197°C.

EXAMPLE 40

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(2-hydroxy-ethyl)benzothiazol-3-ium bromide was purchased from the Eastman Kodak Co.

In a process analogous to Example 3, using appropriately substituted 2-methylbenzothiazoles, alkyl halides, and benzaldehydes, the corresponding compounds were prepared as follows:

EXAMPLE 41

(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide, 246-247°C, dec.

EXAMPLE 42

(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-1-methylnaphtho[1,2-d]thiazol-1-ium toluene-4-sulfonate, 200-210°C.

EXAMPLE 43

(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylbenzothiazol-3-ium chloride, 188-190°C, dec.

EXAMPLE 44

(E)-2-[2-(4-Diethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide, 201-202°C, dec.

-37-

EXAMPLE 45

(E)-2-[2-(4-Dibutylaminophenyl)vinyl]-3-heptyl-benzothiazol-3-ium iodide, 163-164°C.

5

EXAMPLE 46

(E)-3-Heptyl-2-[2-[(4-pyrrolidin-1-yl)phenyl]vinyl]-benzothiazol-3-ium iodide, 227-229°C, dec.

EXAMPLE 47

10 [4-(Dimethylamino)phenylazo]benzothiazole

15 An ice-cold solution of sodium nitrite (1.65 g, 23.9 mmol) in water (15 mL) was added slowly (via syringe) to a stirring mixture at 0°C of 2-aminobenzo-
thiazole (3.78 g, 25.2 mmol) in water (50 mL) and
20 concentrated sulfuric acid (7.0 mL, 126.7 mmol). During addition, the temperature was kept below 5°C. The resultant orange mixture was stirred at 0°C for 15 minutes, then N,N-dimethylaniline was added dropwise causing the mixture to turn dark brown-black. The
25 mixture was stirred at 0°C for 15 minutes, an aqueous solution of sodium acetate (4.32 g in 20 mL of water) was added dropwise, stirred for 1 hour, basified with 25% sodium hydroxide solution to a pH ~12 and allowed to warm to room temperature. The mixture was filtered,
the solid was washed with cold water, recrystallized
from methanol, then chromatographed (silica gel, 2%
methanol in methylene chloride) to give the title
compound as a green solid, mp 243-246°C.

30 In a process analogous to Example 4, using appropriately substituted 2-aminobenzothiazoles and arylamines, the corresponding compounds were prepared as follows:

EXAMPLE 48

35 4-(Benzothiazol-2-ylazo)naphthalen-1-ylamine

-38-

EXAMPLE 49

2-[[4-(Dimethylamino)phenyllazol-6-methoxy-benzothiazole, 213-216°C.

5

EXAMPLE 50

6-Chloro-2-[[4-(dimethylamino)phenyllazol-benzothiazole, 214-218°C.

EXAMPLE 51

10 [4-(6-Methoxybenzothiazol-2-ylazo)naphthalen-1-yl]-dimethylamine, 185-185°C.

EXAMPLE 52

15 Dimethyl[4-(naphtho[1,2-d]thiazol-2-ylazo)naphthalen-1-yl]amine, 146-148°C.

EXAMPLE 53

2-[[4-(Dimethylamino)phenyllazol-6-methoxy-3-methylbenzothiazol-3-ium methylsulfate

20

A solution of [4-(6-methoxy-benzothiazol-2-ylazo)-phenyl]-dimethyl-amine (Example 4b, 0.75 g, 2.40 mmol) and dimethyl sulfate (0.50 mL, 5.28 mmol) in 15 mL of chlorobenzene was heated under nitrogen at 70°C for 3 hours. The solution was cooled and solid formed.

25

The mixture was filtered, the solid was washed with diethyl ether and recrystallized from ethanol to give the title compound as a dark blue-black solid, mp 206-207°C, dec.


30

EXAMPLE 54

2-[[4-(Dimethylamino)phenyllazol-3-methylbenzothiazolium methylsulfate was purchased from the Tennessee Eastman Co.

-39-

Tritiation of Example 12

2-Bromo-4-(dimethylamino)benzaldehyde

To a solution of 4-(dimethylamino)benzaldehyde (5.0 g, 33.5 mmol) in chloroform (30 mL) was added benzoyl peroxide (10 mg). Bromine (5.43 g, 34 mmol) in chloroform (10 mL) was added dropwise to the solution of aldehyde over a 30 minute period. The reaction was stirred an additional hour, and the chloroform solution was washed with 5% NaHCO_3 , dried (MgSO_4), and concentrated. The crude oil was chromatographed on a silica gel column eluted with methylene chloride to

-40-

yield the product as a pale yellow oil (5.21 g, 68% yield).

Analysis calculated for $C_9H_{10}BrNO$:

C, 47.39; H, 4.42; N, 6.14.

5 Found: C, 47.08; H, 4.38; N, 6.13.


Tritiation of 2-bromo-4-(dimethylamino)benzaldehyde

To a solution of the 2-bromo-4-(dimethylamino)-benzaldehyde (.02 g) in anhydrous tetrahydrofuran was
10 added 10% Pd/C (12 mg). The reaction was stirred under an atmosphere of tritium gas for 18 hours. The gas was removed using a gas manifold at $-78^{\circ}C$, and the reaction was filtered through a Celite pad and concentrated. Methanol was added (3×20 mL), and the reaction was
15 reconcentrated to remove any exchangeable tritium. The oil was partitioned between methylene chloride and 5% $NaHCO_3$. The methylene chloride layer was dried ($MgSO_4$), filtered, and concentrated. The crude product was chromatographed on a silica gel column eluted with
20 methylene chloride. The unreacted starting material came off first followed by the tritiated 4-(dimethylamino)benzaldehyde. The product was used without additional purification or characterization.


25 $[^3H]$ -(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide

The procedure used to prepare Example 44 was applied to the reaction of $[^3H]$ -4-(dimethylamino)-benzaldehyde with 3-heptyl-2-methylbenzothiazolium
30 iodide to give the title compounds specific activity 20.54 Ci/mmol.


-41-

Example of ^{131}I -Labeling

10

Example of ^{11}C -Labeling

20

Example of ^{18}F -Labeling


30

- 42 -


Generic Synthetic Schemes

(1) When X=Y is C=C and

5




10



15

20




25 A and B are known in the art or can be prepared by known methods.

- The preferred solvent is water or other polar solvents (methanol, H_2O /methanol mixtures, etc.);
 - "Base" can be NaOH, KOH, LiOH, etc., in the presence of a phase-transfer catalyst, such as $PhCH_2NEt_3Cl$ and other tetraalkylammonium halides.
- 30

(2) When X=Y is C=C and R_3 is anything other than a lone pair of electrons:




- 43 -



- Where L is a leaving group (Br, Cl, p-toulene sulfonate (TSO), etc.);
- Where solvent (1) can be any solvent that the compounds are soluble in, such as ethyl acetate, acetonitrile, ethanol, isopropanol, etc. A preferred solvent (such as ethyl acetate) is one where intermediate A crystallizes as it is formed;
- Temp (1): room temperature - reflux. Preferred temperature range 40-90°C;
- Solvent (2): one in which A is soluble in and which is dehydrating, such as acetic anhydride;
- Temp (2): Typically, the boiling point of solvent (2). Preferred temperature range 80-120°C.



- 44 -

(3) When X=Y is N=N, and



-45-

(4) When X=Y is N=N, and R₃ is anything other than a lone pair of electrons:



- Where L is a leaving group (Cl, Br, TSO, mesylate(MSO), etc.);
- Solvent can be any inert solvent, preferably one in which the product crystallizes as it is formed: chlorobenzene, toluene, etc.;
- Preferred temperature range 50-100°C.

Synthesis of Amyloid Aggregates

Amyloid aggregates were prepared according to methods that are well known to those skilled in the art, and the presence of amyloid fibril aggregates was verified by Congo Red birefringence, a method that is also well known to those skilled in the art.

Insulin Amyloid Aggregates

Burke M.J. and Rougevie M.A., Cross- β Protein Structures. I. Insulin Fibrils. Biochemistry,

-46-

11:2435-243 (1972), which is hereby incorporated by reference, is an example that shows how to make amyloid aggregates having insulin as a component. Briefly, lyophilized insulin protein powder dissolved at 10 mg/mL in 50 mM HCl was alternately heated to 95°C and frozen in dry ice to form amyloid aggregates.

β (1-40) Amyloid Aggregates

Amyloid aggregates containing β (1-40) protein can also be made by methods well known to those skilled in the art. See, for example, Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/ β amyloid peptide analogs. J. Biol. Chem., 267:546-554 (1992), which is hereby incorporated by reference. Briefly, lyophilized β (1-40) protein powder (which may be purchased from BACHEM) was dissolved at 10 mg/mL in hexafluoro-2-propanol and subsequently diluted to 500 μ g/mL in 25 mM sodium phosphate buffer, pH 6 to induce the α -helix to β -sheet transition resulting in aggregate formation.

Competition Assay

The ability of compounds of Formula I to compete with Thioflavin T (ThT) for binding to amyloid aggregates was measured using fluorescence in a 96-well fluorescence plate assay. As a compromise between sensitivity and signal and to facilitate comparisons between different amyloid fibrils, ThT is present at a concentration equal to the K_{mapp} of the particular amyloid fibril type and fibril concentrations yielding a similar fluorescence intensity are used. Insulin: 0.5 μ M ThT, 2 μ g per well. β (1-40): 20 μ M ThT, 5 μ g/well. All solutions are in 25 mM sodium phosphate

-47-

buffer, pH 6.0, and the assay is performed at room temperature.

Using a multichannel pipettor, 100 μ L of dilutions of the compound to be tested (0.001-30 μ M final concentration in 3-fold steps) are placed in the bottom of Corning U-well polystyrene plates (Corning Company, Corning, New York). 50 μ L of ThT are then added to each well. The amyloid fibrils are then added to each well in a volume of 100 μ L rapidly to mix the well contents. The plates are read within 5 to 30 minutes in a Millipore Cytofluor 2350 96-well fluorescence plate reader using an excitation filter of 440 nm (20 nm bandpass) and an emission filter of 485 nm (20 nm bandpass). ThT dye blanks were used to correct for the minimal fluorescence background which are subtracted from all data. Amyloid fibrils do not contribute significantly to the observed signal. Settling of amyloid fibrils does not effect the observed fluorescence as the instrument reads through the bottom of the sample wells.

Results are expressed as % maximal fluorescence (no competing compound). IC_{50} s are defined as the concentration of compound required to reduce ThT fluorescence to 50% of its initial intensity and are estimated by log-logit analysis. The data is shown below in Table 1.

-48-

TABLE 1

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
5	1 (E)-{4-[2-(5-Chlorobenzothiazol-2-yl)vinyl]-phenyl}dimethylamine	>100,000	100,000
	2 (E)-{4-[2-Benzothiazol-2-yl)vinyl]}phenyl}-dimethylamine	>100,000 (F)	1,200
	3 (E)-Dimethyl-{4-[2-(5-methylbenzothiazol-2-yl)-vinyl]phenyl}amine	(F)	900 (F)
	4 (E)-Dimethyl-{4-[2-(6-methylbenzothiazol-2-yl)-vinyl]phenyl}amine	(F)	1,500 (F)
	5 (E)-{2-[2-(4-Dimethylamino-phenyl)vinyl]benzothiazol-6-yl}dimethylamine	>100,000	6,000
10	6 (E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)-vinyl]benzothiazol-3-ium bromide	110	12
	7 (E)-2-[2-(4-Dimethylamino-phenyl)vinyl]-3-ethylbenzothiazol-3-ium iodide	400	6
	8 (E)-2-[2-(4-Dimethylamino-phenyl)vinyl]-1-methylnaphtho[1,2-d]-thiazol-3-ium iodide	210	53

-49-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
5	9 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-methylbenzothiazol-3-ium iodide	1,000	3
	10 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-allylbenzothiazol-3-ium bromide	300	12
	11 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-butylbenzothiazol-3-ium iodide	160	27
	12 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide	93	83
	13 (E)-5-Chloro-2-[2-(4-dimethylaminophenyl)-vinyl]-3-methylbenzothiazol-3-ium iodide	430	5.2
10	14 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-5-fluoro-3-methylbenzothiazol-3-ium iodide	1,000	10
	15 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-benzyl-5-fluorobenzo-thiazol-3-ium bromide	170	32
	16 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3,5-dimethylbenzothiazol-3-ium iodide	400	7.5

-50-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
17	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3,6-dimethylbenzothiazol-3-ium iodide	180	6
5	18 (E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)-vinyl]-6-methylbenzothiazol-3-ium bromide	130	50
19	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide	300	8
20	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-heptyl-6-methoxybenzothiazol-3-ium iodide	140	40
21	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-methyl-6-nitrobenzothiazol-3-ium toluene-4-sulfonate	1,000	12
22	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-1-ethyl-naphtho[1,2-d]-thiazol-1-ium toluene-4-sulfonate	210	41
10	23 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-methylnaphtho[2,3-d]-thiazol-3-ium iodide	120	120

-51-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
24	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-methylnaphtho[2,1-d]-thiazol-3-ium iodide	210	41
5	25 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(4-fluorobenzyl)benzothiazol-3-ium bromide	120	42
26	(E)-3-Biphenyl-4-ylmethyl-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium iodide	240	34
27	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-naphthalen-2-ylmethyl-benzothiazol-3-ium bromide	120	13
28	(E)-3-Biphenyl-2-ylmethyl-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium bromide	100	80
29	(E)-3-(3-Benzoylbenzyl)-2-[2-(4-dimethylaminophenyl)-vinyl]benzothiazol-3-ium bromide	230	130
10	30 (E)-2-[2-(4-Dimethylamino-phenyl)vinyl]-3-(3-phenoxybenzyl)benzothiazol-3-ium bromide	120	180

-52-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
31	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(3-phenylpropyl)benzothiazol-3-ium iodide	200	210
5	32 (E,E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(3-phenylallyl)benzothiazol-3-ium bromide	100	80
33	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(4,4-diphenylbutyl)benzothiazol-3-ium iodide	460	210
34	(E)-3-(3-Benzoyloxypropyl)-2-[2-(4-dimethylamino-phenyl)vinyl]benzothiazol-3-ium iodide	140	52
35	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(4-phenoxybutyl)benzothiazol-3-ium iodide	170	62
36	(E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(5-phenylpentyl)benzothiazol-3-ium iodide	170	93
10	37 (E)-2-[2-(4-Dimethyl-aminophenyl)vinyl]-3-(5-phenoxyphenyl)benzothiazol-3-ium iodide	170	80

-53-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
38	(E)-3-(2-Cyclohexylethyl)- 2-[2-(4-dimethylamino- phenyl)vinyl]benzothiazol- 3-ium iodide	120	52
5	39 (E)-2-[2-(4-Dimethyl- aminonaphthalen-1-yl)- vinyl]-3-heptylbenzo- thiazol-3-ium iodide	160	40
41	(E)-2-[2-(4-Dimethyl- aminonaphthalen-1-yl)- vinyl]-6-methoxy-3- methylbenzothiazol-3-ium iodide	430	26
42	(E)-2-[2-(4-Dimethylamino- naphthalen-1-yl)vinyl]-1- methylnaphtho[1,2-d]- thiazol-1-ium toluene-4- sulfonate	250	42
43	(E)-2-[2-(4-Dimethylamino- phenyl)vinyl]-3-methyl- benzothiazol-3-ium chloride		
44	(E)-2-[2-(4-Diethylamino- phenyl)vinyl]-3-heptyl- benzothiazol-3-ium iodide	140	120
10	45 (E)-2-[2-(4-Dibutylamino- phenyl)vinyl]-3-heptyl- benzothiazol-3-ium iodide	600	90

-54-

TABLE 1 (cont'd)

Example Number	Name	β A(1-40), IC ₅₀ (nM)	Insulin, IC ₅₀ (nM)
46	(E)-3-Heptyl-2-[2-[(4-pyrrolidin-1-yl)phenyl]-vinyl]benzothiazol-3-ium iodide	160	42
5	47 [4-(Dimethylamino)-phenylazo]benzothiazole	22,000	1,200
48	4-(Benzothiazol-2-ylazo)-naphthalen-1-ylamine	120	110
49	2-[[4-(Dimethylamino)-phenyl]azo]-6-methoxybenzothiazole	3,200	700
50	6-Chloro-2-[[4-(dimethylamino)phenyl]azo]benzothiazole	1,300	1,300
51	[4-(6-Methoxybenzothiazol-2-ylazo)naphthalen-1-yl]-dimethylamine	2,500	340
10	52 Dimethyl[4-(naphtho[1,2-d]-thiazol-2-ylazo)naphthalen-1-yl]-amine	52,000	16,000
53	2-[[[(4-Dimethylamino-phenyl)azo)-6-methoxy-3-methylbenzothiazol-3-ium methylsulfate	410	10
54	2-[[[(4-Dimethylamino)-phenyl]azo]-3-methylbenzothiazolium methylsulfate	1,300	60

(F) indicates that the test compound itself is fluorescent and interferes with the assay.

-55-

Binding of [³H]-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide to Amyloid Fibrils


The binding reaction is carried out at room temperature in buffer (25 mM sodium phosphate, pH 6.0 + 0.2 mg/mL chicken ovalbumin (which can be purchased from Sigma). 33 μ L of buffer containing 30,000 cpm of [³H]-2-[2-(4-Dimethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide are added to 33 μ L of diluted test compound in buffer in polyallomer 1.5 mL microfuge tubes (which may be purchased from Beckman). The binding reaction is initiated with 33 μ L of buffer containing 300 ng of insulin amyloid fibrils and vortexing. After 45 minutes, 1.25 mL of buffer are added to each tube, vortexed, and spun at 16,000 XG in a microfuge for 10 minutes. The supernatant is removed by pasteur pipet and the whole tube is placed in a 20 mL scintillation vial for determination of tritium after the addition of Ready-Gel scintillation fluid (Beckman). Nonspecific binding of label to tubes containing no amyloid fibrils or with fibrils in the presence of excess unlabeled 2-[2-(4-dimethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide give the same values and are subtracted from the total binding to obtain specific binding.

Results are expressed as % maximal specific binding. IC₅₀s are defined as the concentration of compound required to reduce [³H]-2-[2-(4-dimethylaminophenyl)vinyl]-3-heptyl benzothiazol-3-ium iodide binding to 50% of its initial amount and are estimated by log-logit analysis. Figures 1 and 2 show the results.


-56-

CLAIMS

1. A method of imaging amyloid deposits, the method comprising:
- a. introducing into a patient a detectable quantity of a labeled compound having the Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof



15 wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration; Z is



- 25 R^1 and R^2 are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, halogen, amino, di(C_1-C_6 alkyl)amino, mono(C_1-C_6 alkyl)amino, nitro, C_1-C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;
- 30 R^3 is a lone pair of electrons, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl or $-(CH_2)_m-A-(CH_2)_n-Q$;
 m is 1 to 6 and n is 0 to 6;

-57-

- 35 A is -O-, -S-, -NR⁴-, C=O, or a single bond;
 Q is phenyl substituted with R⁷ or naphthyl
 substituted with R⁷;
 R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
 hydroxy, halogen, amino, di(C₁-C₆
 40 alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl,
 heteroaryl, aryloxy, -CO-aryl, or arylthio;
 R⁴ and R⁵ are each independently hydrogen, C₁-C₆
 alkyl or -NR⁴R⁵ represents a 5-, 6- or
 7-membered ring containing nitrogen; and
 45 R⁶ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
 hydroxy, halogen, amino, di(C₁-C₆
 alkyl)amino, nitro, or C₁-C₆ thioalkoxy;
 b. allowing sufficient time for the labeled
 compound to become associated with amyloid
 50 deposits; and
 c. detecting the labeled compound associated
 with the amyloid deposits.
2. The method of Claim 1 wherein
 X=Y is C=C or N=N;
 R¹ and R² are each independently hydrogen, C₁-C₆
 alkyl, C₁-C₆ alkoxy, halogen, nitro, C₁-C₆
 5 thioalkoxy, or R¹ and R² combined form a
 benzene, cyclopentane or cyclohexane ring
 that is fused to the phenyl ring;
 R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl,
 (cycloalkyl)alkyl, arylalkenyl,
 10 diarylalkenyl, or -(CH₂)_m-A-(CH₂)_n-Q;
 m is 1 to 5 and n is 0 to 4;
 A is -O-, -S-, or a single bond;
 Q is phenyl substituted with R⁷ or naphthyl
 substituted with R⁷;
 15 R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
 hydroxy, halogen, amino, di(C₁-C₆

-58-

alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl,
aryloxy, -CO-aryl, or arylthio;
20 R⁴ and R⁵ are each independently hydrogen or C₁-C₆
alkyl; and
R⁶ is hydrogen, C₁-C₆ alkyl, or halogen.

3. The method of Claim 1 wherein
X=Y is C=C or N=N;
R¹ and R² are each independently hydrogen, C₁-C₆
5 alkyl, C₁-C₆ alkoxy, halogen, nitro, or R¹
and R² combined form a (4,5), (5,6), or (6,7)
benzene ring that is fused to the phenyl
ring;
R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl,
arylalkenyl, diarylalkyl, or
10 -(CH₂)_m-A-(CH₂)_n-Q;
m is 2 to 4 and n is 0 to 3;
A is -O-, or a single bond;
Q is phenyl substituted with R⁷ or naphthyl
substituted with R⁷;
15 R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
hydroxy, halogen, aryl, aryloxy, or -CO-aryl;
R⁴ and R⁵ are each independently hydrogen, methyl,
ethyl, n-propyl or n-butyl; and
20 R⁶ is hydrogen or halogen.

4. The method of Claim 1 wherein the compound is
(E)-{4-[2-(5-Chlorobenzothiazol-2-yl)vinyl]-
phenyl}dimethylamine;
(E)-{4-[2-Benzothiazol-2-yl)vinyl]}phenyl}-
5 dimethylamine;
(E)-Dimethyl-{4-[2-(5-methylbenzothiazol-2-
yl)vinyl]phenyl}amine;
(E)-Dimethyl-{4-[2-(6-methylbenzothiazol-2-
yl)vinyl]phenyl}amine;

- 10 (E)-{2-[2-(4-Dimethylaminophenyl)vinyl]benzo-
thiazol-6-yl}dimethylamine;
- (E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)-
vinyl]benzothiazol-3-ium bromide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
15 ethylbenzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-
methylnaphtho[1,2-d]thiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
methylbenzothiazol-3-ium iodide;
- 20 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
allylbenzothiazol-3-ium bromide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
butylbenzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
25 heptylbenzothiazol-3-ium iodide;
- (E)-5-Chloro-2-[2-(4-dimethylaminophenyl)-
vinyl]-3-methylbenzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-5-
fluoro-3-methylbenzothiazol-3-ium iodide;
- 30 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
benzyl-5-fluorobenzothiazol-3-ium bromide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,5-
dimethylbenzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3,6-
35 dimethylbenzothiazol-3-ium iodide;
- (E)-3-Benzyl-2-[2-(4-dimethylaminophenyl)-
vinyl]-6-methylbenzothiazol-3-ium bromide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-6-
methoxy-3-methylbenzothiazol-3-ium iodide;
- 40 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
heptyl-6-methoxybenzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
methyl-6-nitrobenzothiazol-3-ium toluene-4-
sulfonate;

-60-

- 45 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-1-ethylnaphtho[1,2-d]thiazol-1-ium toluene-4-sulfonate;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylnaphtho[2,3-d]thiazol-3-ium iodide;
- 50 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-methylnaphtho[2,1-d]thiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-fluorobenzyl)benzothiazol-3-ium bromide;
- (E)-3-Biphenyl-4-ylmethyl-2-[2-(4-
- 55 dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-naphthalen-2-ylmethylbenzothiazol-3-ium bromide;
- (E)-3-Biphenyl-2-ylmethyl-2-[2-(4-
- 60 dimethylaminophenyl)vinyl]benzothiazol-3-ium bromide;
- (E)-3-(3-Benzoylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium bromide;
- 65 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenoxybenzyl)benzothiazol-3-ium bromide
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(3-phenylpropyl)benzothiazol-3-ium iodide;
- (E,E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-
- 70 (3-phenylallyl)benzothiazol-3-ium bromide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4,4-diphenylbutyl)benzothiazol-3-ium iodide;
- (E)-3-(3-Benzoyloxypropyl)-2-[2-(4-
- 75 dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(4-phenoxybutyl)benzothiazol-3-ium iodide;
- (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenylpentyl)benzothiazol-3-ium iodide;

-61-

- 80 (E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(5-phenoxyethyl)benzothiazol-3-ium iodide;
(E)-3-(2-Cyclohexylethyl)-2-[2-(4-dimethylaminophenyl)vinyl]benzothiazol-3-ium iodide;
- 85 (E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-3-heptylbenzothiazol-3-ium iodide;
(E)-2-[2-(4-Dimethylaminophenyl)vinyl]-3-(2-hydroxyethyl)benzothiazol-3-ium bromide;
(E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-6-methoxy-3-methylbenzothiazol-3-ium iodide;
- 90 (E)-2-[2-(4-Dimethylaminonaphthalen-1-yl)vinyl]-1-methylnaphtho[1,2-d]thiazol-1-ium toluene-4-sulfonate;
(E)-2-[2-(4-Diethylaminophenyl)vinyl]-3-methylbenzothiazol-3-ium chloridide;
- 95 (E)-2-[2-(4-Dibethylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide;
(E)-2-[2-(4-Dibutylaminophenyl)vinyl]-3-heptylbenzothiazol-3-ium iodide;
- 100 (E)-3-Heptyl-2-[2-[(4-pyrrolidin-1-yl)phenyl]vinyl]benzothiazol-3-ium iodide;
[4-(Dimethylamino)phenylazo]benzothiazole;
4-(Benzothiazol-2-ylazo)naphthalen-1-ylamine;
- 105 2-[[4-(Dimethylamino)phenyl]azo]-6-methoxybenzothiazole;
6-Chloro-2-[[4-(dimethylamino)phenyl]azo]benzothiazole;
[4-(6-Methoxybenzothiazol-2-ylazo)naphthalen-1-yl]dimethylamine;
- 110 Dimethyl[4-(naphtho[1,2-d]thiazol-2-ylazo)-naphthalen-1-yl]amine;
2-[[4-(Dimethylamino)phenyl]azo]-6-methoxy-3-methylbenzothiazol-3-ium methylsulfate; and

-62-

115 2-[[[(4-Dimethylamino)phenyl]azo]-3-methylbenzothiazolium methylsulfate.


5. A method of delivering a therapeutic agent to an amyloid deposit comprising introducing into a patient a compound having the formula

5

A-B-C

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein A is


10



15

X and Y are each independently C or N and the X=Y double bond has the trans configuration; Z is

20



25

R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

30

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl,

-63-

- (cycloalkyl)alkyl, arylalkenyl, diarylalkyl
or $-(CH_2)_m-A-(CH_2)_n-Q$;
35 m is 1 to 6 and n is 0 to 6;
A is -O-, -S-, $-NR^4$, C=O, or a single bond;
Q is phenyl substituted with R^7 or naphthyl
substituted with R^7 ;
40 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy,
hydroxy, halogen, amino, di(C_1 - C_6
alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl,
heteroaryl, aryloxy, -CO-aryl or arylthio;
 R^4 and R^5 are each independently hydrogen, C_1 - C_6
alkyl or $-NR^4R^5$ represents a 5-, 6-, or
45 7-membered ring containing nitrogen; and
 R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy,
hydroxy, halogen, amino, di(C_1 - C_6
alkyl)amino, nitro or C_1 - C_6 thioalkoxy;
B is a linking moiety or a bond; and
50 C is a therapeutic agent.
- 6 The method of Claim 5 wherein
X=Y is C=C or N=N;
 R^1 and R^2 are each independently hydrogen, C_1 - C_6
alkyl, C_1 - C_6 alkoxy, halogen, nitro, C_1 - C_6
5 thioalkoxy, or R^1 and R^2 combined form a
benzene, cyclopentane, or cyclohexane ring
that is fused to the phenyl ring;
 R^3 is C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl,
(cycloalkyl)alkyl, arylalkenyl, diarylalkyl,
10 or $-(CH_2)_m-A-(CH_2)_n-Q$;
m is 1 to 5 and n is 0 to 4;
A is -O-, -S-, or a single bond;
Q is phenyl substituted with R^7 or naphthyl
substituted with R^7 ;
15 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy,
hydroxy, halogen, amino, di(C_1 - C_6


-64-

- alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl, aryloxy, -CO-aryl, or arylthio;
R⁴ and R⁵ are each independently hydrogen or C₁-C₆ alkyl; and
R⁶ is hydrogen, C₁-C₆ alkyl, or halogen.
- 20
7. The method of Claim 5 wherein
X=Y is C=C or N=N;
R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, nitro, or R¹ and R² combined form a (4,5), (5,6), or (6,7) benzene ring that is fused to the phenyl ring;
R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl, arylalkenyl, diarylalkyl, or
-(CH₂)_m-A-(CH₂)_n-Q;
m is 2 to 4 and n is 0 to 3;
A is -O-, or a single bond;
Q is phenyl substituted with R⁷ or naphthyl substituted with R⁷;
R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, halogen, aryl, aryloxy, or -CO-aryl;
R⁴ and R⁵ are each independently hydrogen, methyl, ethyl, n-propyl or n-butyl; and
R⁶ is hydrogen or halogen.
- 5
- 10
- 15
- 20
8. The method of Claim 5 wherein the patient has Alzheimer's disease or Down's syndrome.
9. The method of Claim 5 wherein the linking moiety is a covalent bond, amino acids, peptide, alkyl chain, hydroxy acid, or diacid.


-65-

10. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising:

- 5 a. administering to a patient an amyloid protein aggregation inhibiting amount of a compound of Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof



15 wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration; Z is



25 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

30 R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

m is 1 to 6 and n is 0 to 6;

A is $-O-$, $-S-$, $-NR^4-$, $C=O$, or a single bond;

35 Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

-66-

40 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, -CO-aryl, or arylthio;
45 R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or - NR^4R^5 represents a 5-, 6- or 7-membered ring containing nitrogen; and
45 R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or C_1 - C_6 thioalkoxy.


11. The method of Claim 10 wherein
X=Y is C=C or N=N;
5 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogen, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;
10 R^3 is C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkenyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;
m is 1 to 5 and n is 0 to 4;
A is -O-, -S-, or a single bond;
Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;
15 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, aryloxy, -CO-aryl, or arylthio;
20 R^4 and R^5 are each independently hydrogen or C_1 - C_6 alkyl; and
 R^6 is hydrogen, C_1 - C_6 alkyl, or halogen.

12. The method of Claim 10 wherein
X=Y is C=C or N=N;

-67-

- R^1 and R^2 are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, nitro, or R^1 and R^2 combined form a (4,5), (5,6), or (6,7) benzene ring that is fused to the phenyl ring;
 R^3 is C_1-C_{10} alkyl, C_2-C_{10} alkenyl, arylalkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;
 m is 2 to 4 and n is 0 to 3;
 A is $-O-$, or a single bond;
 Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;
 R^7 is hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, halogen, aryl, aryloxy, or $-CO-aryl$;
 R^4 and R^5 are each independently hydrogen, methyl, ethyl, n -propyl or n -butyl; and
 R^6 is hydrogen or halogen.

13. A method for determining a compound's ability to inhibit the aggregation of amyloid proteins, the method comprising:
 a. combining solutions of the compound and amyloid proteins;
 b. introducing into the solution a labeled compound of Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof




I

wherein X and Y are each independently C or N and the $X=Y$ double bond has the trans configuration;

- 68 -

Z is

20



25

R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

30

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

35

m is 1 to 6 and n is 0 to 6;

A is $-O-$, $-S-$, $-NR^4-$, $C=O$, or a single bond;

Q is phenyl substituted with R^7 or naphthyl substituted with R^7 ;

40

R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, aryl, heteroaryl, aryloxy, $-CO$ -aryl, or arylthio;

45

R^4 and R^5 are each independently hydrogen, C_1 - C_6 alkyl or $-NR^4R^5$ represents a 5-, 6- or 7-membered ring containing nitrogen; and

R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, nitro, or C_1 - C_6 thioalkoxy;

50

- c. filtering or centrifuging the solution; and
- d. determining the amount of labeled compound in the filtrate or supernatant.

-69-

14. The method of Claim 13 wherein

X=Y is C=C or N=N;

R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, nitro, C₁-C₆ thioalkoxy, or R¹ and R² combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkenyl, or -(CH₂)_m-A-(CH₂)_n-Q;

m is 1 to 5 and n is 0 to 4;

A is -O-, -S-, or a single bond;

Q is phenyl substituted with R⁷ or naphthyl substituted with R⁷;

R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, halogen, amino, di(C₁-C₆ alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl, aryloxy, -CO-aryl, or arylthio;

R⁴ and R⁵ are each independently hydrogen or C₁-C₆ alkyl; and

R⁶ is hydrogen, C₁-C₆ alkyl, or halogen.

15. The method of Claim 13 wherein

X=Y is C=C or N=N;

R¹ and R² are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, nitro, or R¹ and R² combined form a (4,5), (5,6), or (6,7) benzene ring fused to the phenyl group;

R³ is C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, arylalkyl, arylalkenyl, diarylalkyl, or -(CH₂)_m-A-(CH₂)_n-Q;

m is 2 to 4 and n is 0 to 3;

A is -O-, or a single bond;

Q is phenyl substituted with R⁷ or naphthyl substituted with R⁷;


-70-

15 R^7 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, aryl, aryloxy, or -CO-aryl;

R^4 and R^5 are each independently hydrogen, methyl, ethyl, n-propyl, or n-butyl; and
 R^6 is hydrogen or halogen.


16. A compound of the Formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof

5



10 wherein X and Y are each independently C or N and the X=Y double bond has the trans configuration;
 Z is

15



20 R^1 and R^2 are each independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, halogen, amino, di(C_1 - C_6 alkyl)amino, mono(C_1 - C_6 alkyl)amino, nitro, C_1 - C_6 thioalkoxy, or R^1 and R^2 combined form a benzene, cyclopentane, or cyclohexane ring that is fused to the phenyl ring;

25

R^3 is a lone pair of electrons, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, arylalkyl, (heteroaryl)alkyl, (cycloalkyl)alkyl, arylalkenyl, diarylalkyl, or $-(CH_2)_m-A-(CH_2)_n-Q$;

-71-

- 30 m is 1 to 6 and n is 0 to 6;
 A is -O-, -S-, -NR⁴-, C=O, or a single bond;
 Q is phenyl substituted with R⁷ or naphthyl
 substituted with R⁷;
 R⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
35 hydroxy, halogen, amino, di(C₁-C₆
 alkyl)amino, nitro, C₁-C₆ thioalkoxy, aryl,
 heteroaryl, aryloxy, -CO-aryl, or arylthio;
 R⁴ and R⁵ are each independently hydrogen, C₁-C₆
 alkyl or -NR⁴R⁵ represents a 5-, 6- or
40 7-membered ring containing nitrogen; and
 R⁶ is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,
 hydroxy, halogen, amino, di(C₁-C₆
 alkyl)amino, nitro, or C₁-C₆ thioalkoxy,
 and one or more atoms in the compound has been
45 replaced with a radioisotope.
17. The compound of Claim 16 wherein the radioisotope
is ³H, ¹²³I, ¹²⁸I, ¹³¹I, ³⁵S, ¹¹C, ¹⁵O, or ¹⁸F.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 51/04, 47/48 // A61K 101:02, 121:00, 123:00	A3	(11) International Publication Number: WO 97/26919 (43) International Publication Date: 31 July 1997 (31.07.97)
(21) International Application Number: PCT/US97/00251 (22) International Filing Date: 2 January 1997 (02.01.97) (30) Priority Data: 60/010,495 24 January 1996 (24.01.96) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CAPRATHE, Bradley, William [US/US]; 31450 Myrna, Livonia, MI 48154 (US). GILMORE, John, Lodge [US/US]; Apartment 178C, 3695 Greenbrier Boulevard, Ann Arbor, MI 48105 (US). HAYS, Sheryl, Jeanne [US/US]; 2729 Aspen Road, Ann Arbor, MI 48108 (US). JAEN, Juan, Carlos [US/US]; 10680 Red Maple Drive, Plymouth, MI 48170 (US). LEVINE, Harry, III [US/US]; 3790 Bradford Square Drive, Ann Arbor, MI 48103 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 4 December 1997 (04.12.97)
(54) Title: METHOD OF IMAGING AMYLOID DEPOSITS (57) Abstract <p>The present invention provides a method of imaging amyloid deposits and radiolabeled compounds useful in imaging amyloid deposits. The invention also provides a method of delivering a therapeutic agent to amyloid deposits, a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of determining a compound's ability to inhibit aggregation of amyloid proteins.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 97/00251

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K51/04 A61K47/48 //A61K101:02,A61K121:00,A61K123:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LEVINE H: "THIOFLAVINE T INTERACTION WITH SYNTHETIC ALZHEIMER'S DISEASE BETA-AMYLOID PEPTIDES: DETECTION OF AMYLOID AGGREGATION IN SOLUTION"</p> <p>PROTEIN SCIENCE, vol. 2, no. 3, pages 404-410, XP000613188 see abstract see page 408 - page 409, left-hand column; table 1</p> <p style="text-align: center;">--- -/-</p>	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

14 October 1997

Date of mailing of the international search report

24. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 97/00251

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	A CUADRO ET AL.: "Styryl and azastyryl 1,3-benzazoles with anthelmintic activity." IL FARMACO, vol. 47, no. 4, April 1992, PAVIA, IT, pages 477-488, XP002043571 see paragraph CHEMISTRY see tables 1,2 ---	1-17
Y	US 5 039 511 A (QUAY STEVEN C ET AL) 13 August 1991 see abstract see examples ---	1-17
Y	US 4 454 107 A (ROLLESTON RICHARD E) 12 June 1984 see abstract see claims 1-4,9-12 ---	1-17
Y	WO 95 06469 A (CANCER RES CAMPAIGN TECH ; STEVENS MALCOLM FRANCIS GRAHAM (GB); MCC) 9 March 1995 see abstract see examples ---	1-17
Y	NOBUHIRO KURAMOTO: "SYNTHESIS OF AMPHIPHILIC BENZOTHAZOLIUM AZO DYES AND BEHAVIOR OF THEIR MONOLAYERS ON A WATER SURFACE" DYES AND PIGMENTS, vol. 21, no. 3, pages 159-171, XP000372883 see examples ---	1-17
Y	PETERS A T ET AL: "5,6-(6,7-)DICHLOROBENZOTHAZOLYL AZO DYES FOR SYNTHETIC-POLYMER FIBRES" DYES AND PIGMENTS, vol. 18, no. 2, pages 115-123, XP000268097 see examples ---	1-17
Y	HARTMANN H ET AL: "NUCLEOPHILIC SUBSTITUTION ON ARYL AZO COMPOUNDS: PART IV. REACTIONS OF CHLORO-SUBSTITUTED ARYL AZONAPHTHALENES WITH PRIMARY AND SECONDARY AMINES" DYES AND PIGMENTS, vol. 16, no. 2, pages 119-136, XP000208792 see examples ---	1-17

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/00251

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 94 25029 A (JANSSEN PHARMACEUTICA NV ;CLINCKE GILBERT HENRI CAMIEL (BE); TRITS) 10 November 1994 see abstract see examples</p> <p>-----</p>	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/00251

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1-17 in part

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

In view of the large number of compounds, which are defined by the general definition in the independent claims, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see guidelines, Chapter III, paragraph 2.3).

Remark : Although claim(s) 1-4 are directed to a diagnostic method practised on the human/animal body, and claims 5-12 to a method of treatment of the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/00251

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5039511 A	13-08-91	US 5008099 A	16-04-91
		AU 620327 B	20-02-92
		AU 1441988 A	13-10-88
		CA 1302403 A	02-06-92
		DE 3874187 A	08-10-92
		EP 0287909 A	26-10-88
		JP 63290858 A	28-11-88
		US 4933156 A	12-06-90
US 4454107 A	12-06-84	CA 1230342 A	15-12-87
		CA 1222692 A	09-06-87
		EP 0107292 A	02-05-84
		JP 1705690 C	27-10-92
		JP 3074211 B	26-11-91
		JP 59065055 A	13-04-84
WO 9506469 A	09-03-95	AU 7504994 A	22-03-95
		CA 2170508 A	09-03-95
		EP 0721336 A	17-07-96
		JP 9501944 T	25-02-97
WO 9425029 A	10-11-94	AU 6678594 A	21-11-94
		CA 2160365 A	10-11-94
		EP 0696195 A	14-02-96
		HU 73634 A	28-08-96
		JP 8509477 T	08-10-96
		ZA 9402850 A	25-10-95